Effects of CAPE-like compounds on HIV replication in vitro and modulation of cytokines in vivo

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 2, 2005, Pages 372-379

  Ho, Chuan Chen ^a   Lin, Shih Shen ^a   Chou, Ming Yung ^a   Chen, Fang Lung ^a   Hu, Chao Chin ^b   Chen, Chung Shih ^b,c   Lu, Guan Yu ^c   Yang, Chi Chiang ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c KUANG TIEN GENERAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Cytotoxicity; Integrase inhibitors

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)ACRYLIC ACID ETHYL ESTER; 3 (4 BROMOPHENYL)ACRYLIC ACID PHENETHYL ESTER; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAFFEIC ACID METHYL ESTER; CAFFEIC ACID PHENETHYL ESTER; CAFFEIC ACID PHENETHYLDIMETHYL ESTER; EOSIN; FAS ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMATOXYLIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TRYPAN BLUE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KRUSKAL WALLIS TEST; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; CAFFEIC ACIDS; CELL SURVIVAL; CYTOKINES; FEMALE; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PHENYLETHYL ALCOHOL; VIRUS REPLICATION;

EID: 23844472766     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki244     Document Type: Article

References (51)

1. Jeddar A, Khasany A, Ramsaroop VG et al. The antibacterial action of honey: An in vitro study. S Afr Med J 1985; 67: 257-8.
2. Hladon B, Bylka W, Wojtaszek ME et al. In vitro studies on the cytostatic activity of propolis extracts. Arzneim-Forsch Drug Res 1980; 30: 1847-8.
3. Koshihara Y, Neichi T, Murota SL et al. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochim Biophys Acta 1984; 792: 92-7.
4. Rao CV, Desai D, Kaul B et al. Effects of caffeic acid esters on carcinogen-induced mutagenicity and human colon adenocarcinoma cell growth. Chem Biol Interact 1992; 84: 277-90.
5. Guarini L, Su ZZ, Zucker S et al. Growth inhibition and modulation of antigenic phenotype in human melanoma and glioblastoma multiforme cells by caffeic acid phenethyl ester (CAPE). Cell Mol Biol 1992; 38: 513-27.
6. Grunberger D, Banerjee R, Eisinger K et al. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 1988; 44: 230-2.
7. Su ZZ, Grunberger D, Fisher PB. Suppression of adenovirus type 5 EIA-mediated transformation and expression of the transformed phenotype by caffeic acid phenethyl ester (CAPE). Mol Carcinog 1991; 4: 231-42.
8. Lee YJ, Liao PH, Chen WK et al. Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. Cancer Lett 2000; 153: 51-6.
9. Chiao C, Barrett JC, Preston GA et al. Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res 1995; 55: 3576-83.
10. Su ZZ, Fisher PB, Goldstein NI et al. Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells. Anticancer Res 1995; 15: 1841-8.
11. Chen JH, Ho CT, Chin CK et al. Inhibitory effect of caffeic acid phenethyl ester on human leukemia HL-60 cells. Cancer Lett 1996; 108: 211-4.
12. Huang MT, Conney AH, Grunberger D et al. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorborl-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA, and protein in HeLa cells. Carcinogenesis 1996; 17: 761-5.
13. Natarajan K, Aggarwal BB, Grunberger D et al. Caffeic acid phen-ethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc Natl Acad Sci USA 1996; 93: 9090-5.
14. Kensler TW, Taffe BG. Free radicals in tumor promotion. Adv Free Radic Biol Med 1986; 2: 347-87.
15. Jaiswal AK, Grunberger D, Carothers AM et al. Caffeic acid phen-ethyl ester stimulates human antioxidant response element-mediated expression of the NAD(P)H: Quinone oxidoreductase (NQ01) gene. Cancer Res 1997; 57: 440-6.
16. Cardile V, Panico A, Gentile B et al. Effect of propolis on human cartilage and chondrocytes. Life Sci 2003; 73: 1027-35.
17. Lange JM. Strategies for rescue therapy. Antivir Ther 1998; 3: Suppl 4: 75-7.
18. Carosi G, Torti C, Palvarini L et al. HIV-1 pharmacoresistance: clinical and therapeutic implications. J Biol Regul Homeost Agents 1999; 13: 163-71.
19. Telenti A, Paolo Rizzardi G. Limits to potent antiretroviral therapy. Rev Med Virol 2000; 10: 385-93.
20. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-65.
21. Mansky LM. Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virology 2003; 307: 116-21.
22. De Clercq E. Strategies in the development of new antiviral drugs. Nat Rev Drug Discov 2002; 1: 13-25.
23. Lee YJ, Kuo HC, Chu CY et al. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. Biochem Pharmacol 2003; 66: 2281-9.
24. Zhang L, Huang Y, He T et al. HIV type 1 subtype and second-receptor use (letter). Nature 1996; 383: 768.
25. Farzan M, Choe H, Martin K et al. Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med 1997; 186: 405-11.
26. Rucker J, Edinger AL, Sharron M et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997; 71: 8999-9007.
27. Phillips HJ. Dye exclusion tests for cell viability. In: Kruse PF Jr, Patterson MK Jr, eds. Tissue Culture. New York: Academic Press, 1973; 406-8.
28. Alley MC, Scudiero DA, Monks A et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589-601.
29. Huang CR, Lin SS, Chou MY et al. Demonstrating different mode of cell death upon HSV-1 infection in different oral cell populations. Acta Virol 2005; 49: 7-15.
30. Lin SJ, Tsai JH, Tsai CH et al. The in vivo effects of cytokines modulation for balb/c mice fed with a traditional combined Chinese herb-soaked solution, Yi-fey ruenn-hou tea. Immunopharmacol Immunotoxicol 2004; 26: 435-44.
31. Lin SJ, Tsai JH, Tsai CH et al. The in vivo effects of cytokine modulation for Balb/C mice given Canavalia ensiformis (L. : seeds with different heat treatment. Food Chem 2005; 91: 139-45.
32. Lin SS, Chou MY, Ho CC et al. Study of the viral infections and cytokines associated with recurrent aphthous ulceration. Microbes Infect 2005; 7: 635-44.
33. De Clercq E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 1995; 38: 2491-517.
34. Engelman A, Englund G, Orenstein JM et al. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 1995; 69: 2729-36.
35. LaFemina RL, Schneider CL, Robbins HL et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992; 66: 7414-9.
36. Sakai H, Kawamura M, Sakuragi J et al. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol 1993; 67: 1169-74.
37. Fesen MR, Kohn KW, Leteurtre F et al. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993; 90: 2399-403.
38. Billich A, Schauer M, Frank S et al. HIV integrase: High-level production and screening assay for the endonucleolytic activity. Antiviral Chem Chemother 1992; 3: 113-9.
39. Carteau S, Mouscadet JF, Goulaouic H et al. Inhibition of the in vitro integration of Moloney murine leukemia virus DNA by the DNA minor groove binder netropsin. Biochem Pharmacol 1994; 47: 1821-6.
40. Cushman M, Golebiewski WM, Pommier Y et al. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J Med Chem 1995; 38: 443-52.
41. Fesen MR, Pommier Y, Leteurtre F et al. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994; 48: 595-608.
42. Robinson WE. HIV integrase: The next target? Infect Med 1998; 15: 129-37.
43. Burke TR Jr, Fesen MR, Mazumder A et al. Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem 1995; 38: 4171-8.
44. Jiang JD, Wang Y, Roboz J et al. Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound. Cancer Res 1998; 58: 2126-33.
45. Zhao H, Neamati N, Mazumder A et al. Arylamide inhibitors of HIV-1 integrase. J Med Chem 1996; 40: 1186-94.
46. Nagaoka T, Banskota AH, Tezuka Y et al. Caffeic acid phenethyl ester (CAPE) analogues: Potent nitric oxide inhibitors from the Netherlands propolis. Biol Pharm Bull 2003; 26: 487-91.
47. Cohen OJ, Fauci AS. Pathogenesis and medical aspects of HIV-1 infection. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001; 2043-94.
48. Radtke OA, Foo LY, LuY et al. Evaluation of sage phenolics for their anti-leishmanial activity and modulatory effects on interleukin-6, interferon and tumour necrosis factor-alpha-release in RAW 264.7 cells. Z Naturforsch C: Biosci 2003; 58: 395-400.
49. Cheng J, Zhou T, Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-62.
50. Papoff G, Cascino I, Eramo A et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevent cell death in vitro. J Immunol 1996; 156: 4622-30.
51. Chun TW, Engel D, Mizell SB et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5: 651-5.